RES treatment led to a significant decrease in the mRNA and protein levels of STAT3 in the NSCLC+RES group compared to the NSCLC group. This suggests that RES can inhibit the expression of STAT3 in the rat model of NSCLC. The study also proposed the STAT3/HIF‐1α/VEGF pathway as a potential drug target for developing new chemotherapy agents derived from RES for the treatment of NSCLC. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.